Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NeuBase Therapeutics, Inc.    NBSE

NEUBASE THERAPEUTICS, INC.

(NBSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

NEUBASE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
08/13/2020 | 05:13pm EDT

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2020, NeuBase Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three and nine month periods ended June 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.




 (d) Exhibits




Exhibit Number Description
  99.1           Press Release, dated August 13, 2020, Reporting Fiscal Third
               Quarter 2020 Financial Results

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about NEUBASE THERAPEUTICS, INC.
10/27NEUBASE THERAPEUTICS : CEO, Dietrich A. Stephan, Ph.D., to Present Manufacturing..
AQ
10/26NEUBASE THERAPEUTICS' : CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturi..
PU
10/14NEUBASE THERAPEUTICS : Announces Addition of Peter Nielsen, Ph.D., Inventor of P..
AQ
10/13NEUBASE THERAPEUTICS : Announces Addition of Peter Nielsen, Ph.D., Inventor of P..
AQ
10/13NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of ..
GL
10/06NEUBASE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creatio..
AQ
09/29NEUBASE THERAPEUTICS : to Present at the Chardan Virtual 4th Annual Genetic Medi..
AQ
09/28NEUBASE THERAPEUTICS : to Present at the Chardan Virtual 4th Annual Genetic Medi..
AQ
09/28NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Med..
GL
09/18NEUBASE THERAPEUTICS : to Present at the Myotonic Dystrophy Foundation 2020 Virt..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -17,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -9,69x
Yield 2020 -
Capitalization 199 M 199 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 15
Free-Float 78,0%
Chart NEUBASE THERAPEUTICS, INC.
Duration : Period :
NeuBase Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUBASE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 15,67 $
Last Close Price 8,62 $
Spread / Highest target 109%
Spread / Average Target 81,7%
Spread / Lowest Target 50,8%
EPS Revisions
Managers
NameTitle
Dietrich A. Stephan President, Chief Executive Officer & Director
William R. Mann Chief Operating Officer
Samuel I. Backenroth Chief Financial Officer, Secretary & Treasurer
Robert Friedlander Consulting Chief Medical Officer
Danith Ly Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEUBASE THERAPEUTICS, INC.19.72%199
LONZA GROUP AG63.59%47 362
SEAGEN INC.72.34%34 263
IQVIA HOLDINGS INC.3.00%30 511
CELLTRION, INC.32.04%28 321
MODERNA, INC.261.30%27 885